The United Laboratories International Holdings Limited (ULIHF)
The United Laboratories International Holdings Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Yuen Long, HK. The stock last traded at $1.24, up 0.00% on the session, giving a market capitalisation of $2.44B. On trailing twelve-month figures it carries a trailing P/E of 6.81, a net margin of 15.8%. Its beta of 0.29 implies it has historically moved less than the broad market.
The United Laboratories International Holdings Limited functions as a pharmaceutical investment holding company, overseeing the entire spectrum of drug-related activities from initial research and development to manufacturing, distribution, and sales. Its business operations are structured into three main divisions: Bulk Medicine, Intermediate Products, and Finished Products. The company offers a diverse portfolio of medicinal products, including oral and injectable antibiotics, anti-cold and cough remedies, ophthalmic treatments, antiviral drugs, solutions for hepatitis B and diabetes, external dermatological preparations, cardiovascular, cerebrovascular, and nervous system medications, as well as vitamins. Beyond finished pharmaceuticals, it also supplies Active Pharmaceutical Ingredients (APIs), intermediate compounds, and empty gelatin capsules. Further expanding its operations, United Laboratories is involved in the production and sale of soft capsule casings, the management of its intellectual property through trademarks, and pharmaceutical trading. Additionally, the company provides management services. With a substantial global presence, its operations span the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and various international markets. Established in 1990, the company's main office is located in Yuen Long, Hong Kong.
The United Laboratories International Holdings Limited is most often compared with the following Healthcare names: